Foot Orthotic for Early Stage Rheumatoid Arthritis

February 28, 2020 updated by: Morten Bilde Simonsen, Vendsyssel Hospital
The overall purpose of this project is to investigate the neuro adaptations of pain and biomechanical differences between placebo and a custom-made foot orthoses for patients with RA.

Study Overview

Detailed Description

Rheumatoid arthritis (RA) is an autoimmune, chronic, progressive, systemic inflammatory disease leading to substantial pain, disability, and other morbidities. In Denmark there are 40.000 patients with RA. In RA, synovitis, effusion, eventually erosive arthritis, bone loss and weakening of the muscle and tendon apparatus are thought to cause clinically recognizable valgus heel or pes planovalgus deformity. These symptoms gradually cause irreversible joint deformities and changes in the locomotion of muscles3. Over 85% of patients with RA experience painful feet and ankles during the course of the disease. Despite medical developments, foot orthotics (FO) are still an important adjunct treatment and are often prescribed with the intention to stabilize and align the foot. This is due to a number of reasons: 1) persistent foot and ankle problems still occuring even after clinical remission is reached. 2) patients with increased disease activity may have mechanical foot impairments that need treatment in conjunction with systemic management. and 3) patients, who have not responded to or are ineligible for biologic agents, continue to have active foot impairments. However, the scientific research literature within FO treatment has lagged behind clinical practice, often leading the clinician to recommend interventions based on opinion and past experience rather than published evidence9.

Production of FO is an enormous industry. Consequently, there is a great variety of products with different materials, design, manufacturing techniques and procedures. In the literature, some FO have been shown to reduce pain however there is a considerable amount for which the studies are either inconclusive or refute the effect of FO. This might be due to differences in methodology, sparse description of the orthotics and limited information on patient's disease type and stage. However, multidisciplinary studies are still limited and it is, therefore, too early to come up with guidelines about how these interventions affect the human body mechanically from current knowledge. Previous studies have primarily focused on how foot orthotics affect pain, foot function, walking speed, forefoot plantar pressure and gait parameters, while not considering the mechanical principles on which the rationales for FO were originally based. This has led to an abundance of clinical trials that are challenging to interpret, as FO clinical outcomes and FO gait mechanics have not been studied together.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aalborg, Denmark, 9000
        • Aalborg University Hospital
      • Gråsten, Denmark, 6300
        • King Christian X's Hospital for Rhuematic Diseases
      • Hjørring, Denmark, 9800
        • Department for Rheumatology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with RA (EUALAR 2010) without significant damage or with small erosions but without radiological subluxation in the feet, max Larsen rheumatoid arthritis score 224.
  • With clinical (medical) assessed needs for orthotics (e.g. valgus ankle, pes planus, pes planus transversus, and metatarsophalangeal instability).
  • In stable disease phase (no clinically recognizable, swollen joints (but sore joints)).
  • In stable treatment (no change in DMARD, NSAIDs and steroid treatment the last 4 weeks).

Exclusion Criteria:

  • • Patients with RA using, or regularly used FO, or orthopedic shoes within the last 3 months.

    • Clinically significant joint disease (inflammatory or degenerative) of the knee or hip joints (according to the clinician).
    • Clinically significant back disorder (according to the clinician).
    • Patients with severe ischemic or neurological sequelae in the lower extremities.
    • BMI above 32.
    • Not suitable for a MRI scan (e.g. pacemaker, pregnancy or metal within the body).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Standard insole
a flat insole
Sham foot orthotic
Experimental: Foot orthotics
Custom-made foot orthoses
Insoles for shoes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in gait mechanics
Time Frame: Week 4 and 8

Gait analysis will be performed using a 3D marker-based motion capture system from Qualisys, Sweden.

To investigate gait mechanics, detailed patient-specific musculoskeletal (MS) computer models will be created based on clinical medical images (MRI), anthropometrics and motion capture data. The models will be created utilizing a musculoskeletal computer modeling software AnyBody Modeling System (AMS). A detailed cadaver-based model The Twente Lower Extremity Model 2.0 (TLEM 2.0) is developed for AMS to obtain patient-specific architecture, scale bones, joints, and muscles attachments relative to the patient in combination with image-based morphing techniques. These models will be used to estimate joint angles, joint torques, muscle forces and joint forces of the ankle, knee and hip joint.

Week 4 and 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in foot pressure distribution
Time Frame: Week 4 and 8

Motion capture

A pressure insole (2-3 mm thick) system (PedarX, Novel) will be placed in the patient's shoe attached to a small computer. It is a commercial available system that can measure accurate and reliable pressure distribution for monitoring local loads between the foot and the FO.

Week 4 and 8
Questionnaire - Pain - Visual analog scale
Time Frame: Week 0, 4 and 8
0-10 scale from no pain to highest possible.
Week 0, 4 and 8
Insole wearing time
Time Frame: From week 4 to 8
Measured by temperature sensor (Orthotimer). Orthotimer is an electronic microsensor that documents the wearing time of orthopaedic devices. It is small and flat thermometer, (9 x 1 x 4.5 mm) and will be integrated in the handed-out FO. The sensor stores time, date and temperature every 15 minutes. This information allow for accurate measurements of how often the patients uses the FO.
From week 4 to 8
Pain - Pressure pain threshold
Time Frame: Week 0, 4 and 8
To investigate pressure pain threshold (PPT) a handheld algometer will be used. An algometer is an instrument used to measure the pain threshold in relevant areas of the leg, foot and arm. The pain threshold is defined as the point where the pressure is experienced as pain. The pressure increases gradually with an interval until the pain is experienced and the patient presses a stop button. Each measurement is repeated 3 times in each session.
Week 0, 4 and 8
Pain mapping
Time Frame: Week 0, 4 and 8
Subjects will be asked to draw their perceived pain on pain mapping drawings. Drawings will be scanned and layered and averaged though MATLAB, version 2017B (The MathWorks, Inc., Natick, Massachusetts, USA). The area of Pain will be measured using ImangeJ v.1.8.0_112 (National Institutes of Health, Madison, Wisconsin, USA).
Week 0, 4 and 8
Wearable activity monitor
Time Frame: From week 0 to week 8
A commercial available accelerometer based activity monitor (Polar M200) will be lent to the participants. The device will be used to monitor the participant's activity. Participants will be instructed to use the device during the two months they are involved in the project, during the placebo period and during FO treatment.
From week 0 to week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Morten B Simonsen, MSc, Aalborg University, Department of Health Science and Technology and Centre for Clinical Research, North Denmark Regional Hospital, Aalborg University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2018

Primary Completion (Actual)

November 1, 2019

Study Completion (Actual)

December 1, 2019

Study Registration Dates

First Submitted

May 8, 2018

First Submitted That Met QC Criteria

June 18, 2018

First Posted (Actual)

June 19, 2018

Study Record Updates

Last Update Posted (Actual)

March 3, 2020

Last Update Submitted That Met QC Criteria

February 28, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis

Clinical Trials on Standard insole

3
Subscribe